title: Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
abstract: OBJECTIVE
  EO9 is a new synthetic bioreductive alkylating indoloquinone, with preferential activity against solid tumors and higher antitumor activity under anaerobic conditions compared with aerobic conditions. In preclinical models EO9 demonstrated no major organ toxicity. The aim of the present phase I study was to determine the toxicities and the maximal tolerated dose (MTD) of EO9 administered as a 5-min i.v. infusion weekly to patients with solid cancers.
  
  
  METHODS
  Twenty-eight patients entered the study. The dose was escalated from 2.7 mg/m2 according to a Fibonacci-like schedule.
  
  
  CONCLUSIONS
  The dose-limiting toxicity was proteinuria. No other major toxicities were detected and in particular there was no significant increase in serum creatinine. This was in contrast to findings in a previous phase I trial using EO9 in a 3-weekly schedule, where a number of patients experienced severely decreased kidney function. The MTD in the present study was 15.0 mg/m2 weekly and the recommended dose for phase II studies was 12.0 mg/m2 weekly. Compared with 3-weekly EO9, the dose intensity could be increased from 22 mg/m2 to 36 mg/m2 with the weekly administration. Phase II studies have been performed by the EORTC Early Clinical Study Group in advanced breast, gastric, colorectal, pancreatic, and non-small-cell lung cancer.
authors.affiliation: The Norwegian Radium Hospital, Oslo.
authors.forename: S
authors.initials: S
authors.lastname: Aamdal
authors.forename: B
authors.initials: B
authors.lastname: Lund
authors.forename: I
authors.initials: I
authors.lastname: Koier
authors.forename: M
authors.initials: M
authors.lastname: Houten
authors.forename: J
authors.initials: J
authors.lastname: Wanders
authors.forename: J
authors.initials: J
authors.lastname: Verweij
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001388:Aziridines / Q000008:administration & dosage / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D045563:Indolequinones; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D001388:Aziridines; D045563:Indolequinones; D007211:Indoles; C060817:apaziquone